Nobias Therapeutics, a clinical-stage company developing novel small-molecule therapeutics for rare diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted rare pediatric disease designation (RPDD) and orphan drug designation (ODD) to the…
FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Nobias Therapeutics for Treatment of 22q11.2 Deletion Syndrome
This post was originally published on this site